Sun-Ranbaxy merger hits roadblock & Maruti to recall 3,800 Ciaz units to check fault in clutch system

Sun-Ranbaxy:-

Generic drugs maker Sun Pharma’s merger with ailing Ranbaxy has hit the roadblock as the company has not received the approval from Competition Commission of India(CCI). The competition regulator was supposed to come out with its decision by end of November and it is learnt that the regulator still has not given its nod to the $4 billion merger.Regulatory approval from India’s CCI and America’s Federal Trade Commission (FTC) are yet to be received for the biggest merger and acquisition dealin pharma sector in Asia Pacific region this year.

Maruti Suzki :-

Maruti Suzuki, India's largest car maker, said it would recall nearly 3,800 units of Ciaz to check a suspected fault in the vehicle's clutch operation system. Launched in October this year, Ciaz the mid-sized sedan competing against the segment best-seller Honda City had received a healthy response from the customers which pushed it to the second spot beating Hyundai's Verna. The Ciaz recall, which can potentially cause inconvenience to its owners, comes just two months after the car market leader announced a recall of 69,555 units of Dzire, Swift and Ritz in September to repair a wiring harness fitment.